Table 2

Clinicopathological findings in patients on sirolimus versus other immunosuppressive therapy

Sirolimus n = 16

Non-Sirolimus n = 12

P, value


Age, mean, years

51.1 ± 13.25

54.3 ± 15.39

ns


Gender, M*

10 (62.5)

8 (66.7)

ns


F

6 (37.5)

4 (33.3)

ns


Time to lung biopsy, mean, months

44.7 ± 52.04

128.3 ± 89.32

0.01


Neoplasia, total, n (%)

2 (12.5)

7 (58.3)

0.03


Carcinoma, n (%)

1 (6.25)

4 (33.3)

ns


Lymphoproliferative disorders, n (%)

1 (6.25)

3 (25.0)

ns


Diffuse parenchymal lung disease, n (%)

6 (37.5)

3 (25.0)

ns


PH, n (%)

2 (12.5)

1 (8.3)

ns


PH and DAD, n (%)

1 (6.25)

0

-


PH and PAP, OP, n (%)

1 (6.25)

0

-


OP, n (%)

2 (12.5)

1 (8.3)

ns


PAP, n (%)

0

1 (8.3)

-


Necrosis/infectious granulomas, n (%)

4 (25.0)

1 (8.3)

ns


Minimal histological findings, n (%)

4 (25.0)

1 (8.3)

ns


(*) -M male; F female; PH pulmonary hemorrhage; DAD diffuse alveolar damage; PAP pulmonary alveolar proteinosis; OP organizing pneumonia; ns, not statistically significant

Kirby et al. Diagnostic Pathology 2012 7:25   doi:10.1186/1746-1596-7-25

Open Data